Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Charlene Knape"'
Autor:
Brendan Knapp, Laura Mezquita, Siddhartha Devarakonda, Mihaela Aldea, Saiama N. Waqar, Kym Pepin, Jeffrey P. Ward, Angela Botticella, Karen Howarth, Charlene Knape, Clive Morris, Ramaswamy Govindan, Benjamin Besse, Daniel Morgensztern
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionCirculating tumor DNA (ctDNA) testing may identify patients at high risk for recurrence following chemoradiation (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC). We evaluated the feasibility of ctDNA testing on a readily
Externí odkaz:
https://doaj.org/article/bdec53ddcf914269b586e80415fd720d
Autor:
Marla Lipsyc-Sharf, Elza C. de Bruin, Katheryn Santos, Robert McEwen, Daniel Stetson, Ashka Patel, Gregory J. Kirkner, Melissa E. Hughes, Sara M. Tolaney, Ann H. Partridge, Ian E. Krop, Charlene Knape, Ute Feger, Giovanni Marsico, Karen Howarth, Eric P. Winer, Nancy U. Lin, Heather A. Parsons
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(22)
PURPOSE To examine the prevalence and dynamics of circulating tumor DNA (ctDNA) and its association with metastatic recurrence in patients with high-risk early-stage hormone receptor–positive breast cancer (HR+ BC) more than 5 years from diagnosis.
Autor:
Maria Coakley, Prithika Sritharan, Guillermo Villacampa, Claire Swift, Kathryn Dunne, Lucy Kilburn, Katie Goddard, Patricia Rojas, Andy Joad, Warren Emmett, Charlene Knape, Karen Howarth, Peter S. Hall, Catherine Harper-Wynne, Tamas Hickish, Iain Macpherson, Alicia F. Okines, Andrew M. Wardley, Duncan Wheatley, Simon Waters, Rosalind Cutts, Isaac Garcia-Murillas, Judith Bliss, Nicholas Turner
Publikováno v:
Cancer Research. 83:PD5-03
Background: Detection of circulating tumour DNA (ctDNA) in patients (pts) who have completed treatment for early-stage breast cancer is associated with a high risk of future relapse. Identifying those at high risk of subsequent relapse may allow tail
Autor:
Mitchell J. Elliott, Zachary Veitch, Philippe Bedard, Eitan Amir, Aaron Dou, Jesus Fuentes Antras, Michelle Nadler, Nicholas Meti, Nancy Gregorio, Elizabeth Shah, Helen Chow, Nathan Campbell, Samantha Terrell, Charlene Knape, Karen Howarth, Lillian Siu, Hal Berman, David W. Cescon
Publikováno v:
Cancer Research. 83:P6-01
Background: ctDNA dynamics are associated with treatment response, and ctDNA detection following treatment is associated with disease recurrence in early breast cancer (EBC). Highly sensitive assays may permit effective risk stratification and guide
Autor:
Marla Lipsyc-Sharf, Elza De Bruin, Katheryn Santos, Robert McEwen, Daniel Stetson, Ashka Patel, Gregory J. Kirkner, Melissa E. Hughes, Sara M. Tolaney, Ian E. Krop, Charlene Knape, Ute Feger, Giovanni Marsico, Karen Howarth, Eric P. Winer, Nancy U. Lin, Heather Anne Parsons
Publikováno v:
Journal of Clinical Oncology. 40:103-103
103 Background: Hormone receptor–positive breast cancer (HR+ BC) is the most common cause of BC-related death. Over half of metastatic recurrences occur ≥ 5 years (y) from diagnosis. Detection of minimal residual disease (MRD) via circulating tum
Autor:
Kirsty Taylor, Jinfeng Zou, Marcos Aurelio Fonseca Magalhaes Filho, Karen Howarth, Giovanni Marsico, Samantha Terrell, Gregory Jones, Charlene Knape, Tim Forshew, Marc Oliva, Anna Spreafico, Aaron Richard Hansen, Simon McDade, Victoria M. Coyle, Mark Lawler, Elena Elimova, Scott Victor Bratman, Lillian L. Siu
Publikováno v:
Journal of Clinical Oncology. 40:6052-6052
6052 Background: Immuno-oncology agents (IO) have become standard-of-care in the treatment of R/M HNSCC, but only a subset of patients (pts) benefit. Highly sensitive quantification of plasma circulating tumor DNA (ctDNA) may permit real time assessm
Autor:
Wolfgang Janni, Jens Huober, Sophia Huesmann, Christodoulos Pipinikas, Tatjana Braun, Volkmar Müller, Giovanni Marsico, Angelina Fink, Paula Freire-Pritchett, Karin Koretz, Charlene Knape, Amelie deGregorio, Brigitte Rack, Thomas WP Friedl, Lisa Wiesmueller, Peter Möller, Karen Howarth, Klaus Pantel, Nitzan Rosenfeld
Publikováno v:
Cancer Research. 82:P2-01
BACKGROUNDDetection of minimal residual disease (MRD) using circulating tumor DNA (ctDNA) represents an attractive alternative to imaging, currently considered the gold standard in routine surveillance of early breast cancer (BrCa) following primary
Autor:
Stephen R. D. Johnston, Ian E. Smith, Alistair Ring, Rosalind J. Cutts, Maria Coakley, Mitch Dowsett, Nicholas C. Turner, Malcolm Perry, Peter M. Ellis, Isaac Garcia-Murillas, Anthony Skene, Abigail Evans, Charlene Knape, Duncan Wheatley, Lara Ulrich, Karen Howarth, S. Russell, Warren Emmett
Publikováno v:
Cancer Research. 81:536-536
Introduction: Detection of circulating tumor DNA (ctDNA) presents a strategy to identify Molecular Residual Disease (MRD) in patients with breast cancer. Tools capable of detecting ctDNA at lower concentrations are needed to increase sensitivity and
Autor:
Carlo Di Mario, Stefan Verheye, Saqib Chowdhary, John A. Ormiston, Alexandra J. Lansky, Dennis Donohoe, Mathias Vrolix, Charlene Knape, William Wijns, Danny Schoors, Walter Desmet, Hiram G. Bezerra, Dan Rusinaru
Publikováno v:
Catheterization and Cardiovascular Interventions. 86:1141-1150
Objectives We studied coronary vasomotion in patients treated with the Mistent® absorbable polymer sirolimus-eluting stent (APSES) and in patients implanted with the Endeavor® zotarolimus-eluting stent (ZES). Background First generation (1st-gen) d
Autor:
Guilherme F. Attizzani, Robert Whitbourn, Dennis Donohoe, John A. Ormiston, Jim Stewart, Mark Webster, Peter J. Fitzgerald, David E. Kandzari, Charlene Knape, Alexandra J. Lansky, Mathias Vrolix, William Wijns
Publikováno v:
JACC: Cardiovascular Interventions. 6(10):1026-1034
Objectives This first-in-human multicenter study sought to examine prospectively the safety and efficacy of a new, cobalt chromium thin-strut, coronary absorbable polymer–coated, sirolimus-eluting stent. Background Bioabsorbable polymers on drug-el